Hyperactivity induced by prenatal BrdU exposure across several experimental conditions

Congenital Anomalies

Volumn 51, Issue 4, 2011, Pages 177-182

  Kuwagata, Makiko ^a,b   Ogawa, Tetsuo ^b   Muneoka, Katsumasa ^b   Shioda, Seiji ^b  

^a HATANO RESEARCH INSTITUTE   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BrdU; Developmental neurotoxicity; Hyperactivity; Prenatal exposure; Reproducibility

Indexed keywords

BROXURIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FISCHER 344 RAT; HYPERACTIVITY; NEUROTOXICITY; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; BROMODEOXYURIDINE; DISEASE MODELS, ANIMAL; FEMALE; HYPERKINESIS; MICE; MICE, INBRED ICR; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SPECIES SPECIFICITY;

EID: 82055172312     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2011.00331.x     Document Type: Article

References (33)

1. Archer J (1973) Tests for emotionality in rats and mice: A review. Anim Behav 21: 205-235.
2. Chaturvedi RK, Shukla S, Seth K etal. (2006) Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis 22: 421-434.
3. Crofton KM, Foss JA, Hass U, Jensen KF, Levin ED, Parker SP (2008) Undertaking positive control studies as part of developmental neurotoxicity testing: A report from the ILSI Research Foundation/Risk Science Institute expert working group on neurodevelopmental endpoints. Neurotoxicol Teratol 30: 266-287.
4. Crofton KM, Makris SL, Sette WF, Mendez E, Raffaele KC (2004) A qualitative retrospective analysis of positive control data in developmental neurotoxicity studies. Neurotoxicol Teratol 26: 345-352.
5. Diaz-Veliz G, Soto V, Dussaubat N, Mora S (1989) Influence of the estrous cycle, ovariectomy and estradiol replacement upon the acquisition of conditioned avoidance responses in rats. Physiol Behav 46: 397-401.
6. Fiore M, Aloe L, Westenbroek C, Amendola T, Antonelli A, Korf J (2001) Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: Consideration for a role of nerve growth factor and brain derived neurotrophic factor. Neurosci Lett 309: 113-116.
7. Hall S (1934) Emotional behavior in the rat. I. Defecation and urination as measures of individual differences inemotionality. J Comp Physiol Psychol 18: 385-403.
8. Hall S (1936) Emotional behavior in the rat. III. The relationship between emotionality and ambulatory activity. J Comp Physiol Psychol 22: 345-352.
9. Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 162: 1-10.
10. Jans LA, Lieben CK, Blokland A (2007) Influence of sex and estrous cycle on the effects of acute tryptophan depletion induced by a gelatin-based mixture in adult Wistar rats. Neuroscience 147: 304-317.
11. Kolb B, Pedersen B, Ballermann M, Gibb R, Whishaw IQ (1999) Embryonic and postnatal injections of bromodeoxyuridine produce age-dependent morphological and behavioral abnormalities. J Neurosci 19: 2337-2346.
12. Kuwagata M, Muneoka KT, Ogawa T, Takigawa M, Nagao T (2004) Locomotor hyperactivity following prenatal exposure to 5-bromo-2′-deoxyuridine: Neurochemical and behavioral evidence of dopaminergic and serotonergic alterations. Toxicol Lett 152: 63-71.
13. Kuwagata M, Nagao T (1998) Behavior and reproductive function of rat male offspring treated prenatally with 5-bromo-2′-deoxyuridine. Reprod Toxicol 12: 541-549.
14. Kuwagata M, Ogawa T, Nagata T, Shioda S (2007) The evaluation of early embryonic neurogenesis after exposure to the genotoxic agent 5-bromo-2′-deoxyuridine in mice. Neurotoxicology 28: 780-789.
15. Kuwagata M, Saito Y, Usumi K, Ono H, Nagao T (2001) Disruption of brain development in male rats exposed prenatally to 5-bromo-2′-deoxyuridine. Congenit Anom (Kyoto) 41: 312-320.
16. Miller MW, Nowakowski RS (1988) Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res 457: 44-52.
17. Miserendino MJ, Haile CN, Kosten TA (2003) Strain differences in response to escapable and inescapable novel environments and their ability to predict amphetamine-induced locomotor activity. Psychopharmacology (Berl) 167: 281-290.
18. Morris SM (1991) The genetic toxicology of 5-bromodeoxyuridine in mammalian cells. Mutat Res 258: 161-188.
19. Muneoka K, Kuwagata M, Iwata M, Shirayama Y, Ogawa T, Takigawa M (2006) Dopamine transporter density and behavioral response to methylphenidate in a hyperlocomotor rat model. Congenit Anom (Kyoto) 46: 155-159.
20. Nagao T, Kuwagata M, Saito Y (1998) Effects of prenatal exposure to 5-bromo-2′-deoxyuridine on the developing brain and reproductive function in male mouse offspring. Reprod Toxicol 12: 477-487.
21. Nagao T, Sato M, Kuwagata M, Saito Y (1997) Effects of prenatal exposure to 5-bromo-2′-deoxyuridine on reproductive function in male mouse offspring. Reprod Toxicol 11: 663-673.
22. OECD (2007) Organization for Economic Cooperation and Development (OECD) Guideline for the Testing of Chemicals No. 426: Developmental Neurotoxicity Study.
23. Ogawa T, Kuwagata M, Muneoka KT, Shioda S (2005) Neuropathological examination of fetal rat brain in the 5-bromo-2′-deoxyuridine-induced neurodevelopmental disorder model. Congenit Anom (Kyoto) 45: 14-20.
24. Orito K, Morishima A, Ogawa T etal. (2004) Behavior abnormalities in rat offspring prenatally exposed to 5-bromo-2′-deoxyuridine. Twenty First International Neurotoxicology Conference, Abstract A-137. Honolulu, Hawaii.
25. Porsolt D, McArthur A, Lenegre A (1993) Psychotropic screening procedures. In: van Haaren F, ed. Methods in Behavioral Pharmacology: Techniques in the Behavioral and Neural Sciences. Elsevier, New York, pp. 23-51.
26. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006) Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358.
27. Sekerkova G, Ilijic E, Mugnaini E (2004) Bromodeoxyuridine administered during neurogenesis of the projection neurons causes cerebellar defects in rat. J Comp Neurol 470: 221-239.
28. Soriano E, Del Rio JA (1991) Simultaneous immunocytochemical visualization of bromodeoxyuridine and neural tissue antigens. J Histochem Cytochem 39: 255-263.
29. Takahashi T, Goto T, Miyama S, Nowakowski RS, Caviness VS, Jr. (1999) Sequence of neuron origin and neocortical laminar fate: Relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci 19: 10357-10371.
30. U.S. EPA (1998) Health Effects Guidelines OPPTS 870.6300 Developmental Neurotoxicity Study.
31. Walsh RN, Cummins RA (1976) The Open-Field Test: A critical review. Psychol Bull 83: 482-504.
32. Wang Y, Zhang QJ, Liu J etal. (2010) Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease. Brain Res 1310: 189-199.
33. Young R, Glennon RA (2008) MDMA (N-methyl-3, 4-methylenedioxyamphetamine) and its stereoisomers: Similarities and differences in behavioral effects in an automated activity apparatus in mice. Pharmacol Biochem Behav 88: 318-331.